Although the U.S. leads the world in biotechnology discoveries and investments, other countries are making investments in production-scale infrastructure that are enabling them to rapidly close the gap. In particular, China has made biotechnology a core part of its national strategy, and is investing heavily in developing the industry. In response, the U.S. government is formulating a comprehensive strategy to lead the world in emerging biotechnologies across sectors such as fuel, agriculture, healthcare, and defense. 

 A new white paper by Washington CORE organizes and analyzes the key developments for biotechnology development in the U.S., including Trump administration policies, debates in Congress, initiatives by state governments, the major industry organizations that are shaping the emerging bio ecosystem, trends in various application fields, and the potential for Japan-U.S. collaboration.  

The white paper was shared with a small number of clients and is available on request.